Key Summary Points {#d30e368}
==================

**Why carry out this study?**Numerous studies have established the safety and effectiveness of iStent *inject* trabecular micro-bypass implantation in combination with cataract surgery in eyes with different types of glaucoma. However, their outcomes remain understudied in normal-tension glaucoma (NTG).The present study aims to assess the 1-year outcomes of iStent *inject* implantation with cataract surgery exclusively in eyes with NTG.**What was learned from the study?**Intraocular pressure (IOP) at 12 months was significantly lower than preoperative IOP (12.3 ± 2.6 mmHg versus 15.8 ± 2.9 mmHg, respectively; *p* \< 0.001). At 12 months, all eyes achieved IOP ≤ 18 mmHg (versus 74% preoperatively), 92% of eyes achieved IOP ≤ 15 mmHg (versus 45% preoperatively), and half (50%) of the eyes achieved IOP ≤ 12 mmHg (versus 15% preoperatively).Medication burden at 12 months was significantly reduced from preoperative (0.45 ± 0.86 medications versus 1.50 ± 1.28 medications, respectively; *p* \< 0.001). All eyes either maintained or decreased topical medications from baseline, with 66% of eyes eliminating ≥ 1 medication and 29% of eyes eliminating ≥ 2 medications from their preoperative regimen.Implantation of two second-generation trabecular micro-bypasses combined with cataract surgery is efficacious in reducing IOP and medication burden with a favorable safety profile in eyes with mild-to-severe NTG.

Introduction {#Sec2}
============

Glaucoma is the leading cause of irreversible blindness worldwide and is expected to affect 111 million people by 2040 \[[@CR1]\]. Current approaches to glaucoma treatment are focused on decreasing intraocular pressure (IOP)---the only modifiable risk factor proven to be associated with disease progression \[[@CR2], [@CR3]\]. Normal-tension glaucoma (NTG) is a variant of open-angle glaucoma (OAG) and is characterized by glaucomatous damage despite having IOP values constantly \< 21 mmHg \[[@CR4]\]. The elevated IOP has often been considered an integral diagnostic feature of glaucoma, making detection of NTG particularly challenging; thus normotensive NTG patients frequently have been under-diagnosed and under-treated \[[@CR5]\]. Despite normal IOP values, the Collaborative Normal Tension Glaucoma Study (CNTGS) evidenced a strong association between IOP lowering and deceleration in disease progression \[[@CR3], [@CR6]\]. It was concluded that IOP reduction, whether medically or surgically, remains the most important component of NTG treatment \[[@CR3], [@CR6]\].

Micro-invasive glaucoma surgery (MIGS) is a growing area of surgical glaucoma treatment options that offers IOP-reducing efficacy alongside a superior safety profile compared to traditional glaucoma surgeries \[[@CR7]\]. These ab-interno, tissue-sparing MIGS procedures lead to quicker visual recovery, spare conjunctival tissue for future glaucoma surgeries \[[@CR8]\] and can be undertaken as a standalone procedure or combined with cataract or other MIGS surgeries \[[@CR9], [@CR10]\]. The introduction of MIGS has stimulated a more proactive, surgical approach in treating mild-to-moderate OAG \[[@CR11]\]. Recently, MIGS procedures have been used with or without the traditional early interventions of medication and/or laser trabeculoplasty \[[@CR12]\]. A surgical intervention avoids the limitations associated with the glaucoma medications such as low patient adherence, side effects, ocular surface damage and costs \[[@CR13]--[@CR17]\], while also limiting IOP fluctuations compared to medical therapy \[[@CR18]\].

iStent trabecular micro-bypass (Glaukos Corp., San Clemente, CA, USA) was the first MIGS device to receive the US Food and Drug Association (FDA) approval for treatment of mild-to-moderate OAG. Recently, the second-generation iStent *inject* trabecular micro-bypass (iStent *inject*) was approved for the same. Both devices are designed to restore natural physiologic outflow by creating a patent bypass through the trabecular meshwork into Schlemm's canal for aqueous humor to exit the anterior chamber. In addition to some fundamental differences in design, iStent *inject* has the advantage of coming pre-loaded with two stents, which allows placement in separate regions of the trabecular meshwork to access a larger number of collector channels. Additionally, the stents contain a central lumen with four side outlets allowing a multidirectional aqueous outflow.

iStent *inject* has been extensively studied, and its efficacy and safety have been established in primary OAG, secondary OAG and ocular hypertension \[[@CR19]--[@CR27]\]; however, to our knowledge, no study has examined its use exclusively in NTG. Here, we aimed to evaluate the 1-year outcomes of iStent *inject* with concomitant cataract surgery in patients with mild-to-severe NTG.

Methods {#Sec3}
=======

Participants and Design {#Sec4}
-----------------------

This retrospective multicenter consecutive case series comprised eyes with normal-tension glaucoma and cataract that underwent cataract extraction with concomitant implantation of two second-generation trabecular micro-bypass stents (iStent *inject*) (CE-TMS). All procedures were performed between 2016 and 2019, by three surgeons (P.H, C.C, M.S) at three separate ophthalmology centers. The inclusion criteria included: age \> 18 years; clinical diagnosis of NTG; presence of cataract and the need for reduction of IOP or glaucoma medication in that eye; a minimum of 12 months postoperative follow-up data. NTG was defined as a patient having no history of maximal untreated IOP \> 21 mmHg and no history of trauma. Exclusion comprised the inability to visualize nasal trabecular meshwork, elevated episcleral venous pressure and ocular inflammation. At the time of this study, iStent *inject* was indicated for mild-to-moderate open-angle glaucoma; however, to increase the generalizability of our findings we did not exclude any eyes based on glaucoma severity or history of prior glaucoma surgery.

The study was approved by the Ethics Committee of the Hôpital Maisonneuve-Rosemont in Montreal, Canada. All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Voluntary informed consent was obtained from all participants before the surgery.

Surgical Technique {#Sec5}
------------------

To ensure maximum proximity of the stent to the collector channel ostia two areas, located at least two clock hours apart in the nasal angle with greater trabecular pigmentation \[[@CR28]\] or with evidence of focal blood reflux \[[@CR8]\], were identified and marked at the corneal limbus \[[@CR29]\]. Following the instillation of topical anesthesia, a small clear corneal incision was made temporally through which the iStent *inject* injector was inserted. Following visualization of the angle using gonioscopy, the two stents were implanted into the trabecular meshwork next to the collector channel markings. Through the same corneal incision, P.H. performed the phacoemulsification prior to the insertion of iStent (*n* = 26) while C.C. and M.S. performed this step following the iStent insertion (*n* = 36).

The glaucoma medication regimen was adjusted, case by case, as per the surgeon's discretion according to the severity of the disease and the preoperative IOP. The standard postoperative regimen for P.H. comprised one oral acetazolamide 500 mg on the first evening, 1 week of topical moxifloxacin (three times per day), 1 month of topical nepafenac (three times per day) and topical loteprednol, which was tapered from four times per day over 2 weeks. The regimen for C.C. and M.S. included 2 weeks of Chloramphenicol, Ketorolac and Maxidex/Prednefrin Forte, each used four times per day followed by 2 weeks of Ketorolac and of Maxidex/Prednefrin used twice per day.

Outcome Measures and Data Analysis {#Sec6}
----------------------------------

Demographic, baseline and postoperative clinical data were extracted from patients' charts. Efficacy measures included changes in IOP (measured using the Goldman applanation tonometry) and anti-glaucoma medications (scored according to the number of active pharmacologic classes) \[[@CR30], [@CR31]\]. Safety comprised intra- or postoperative adverse events, best-corrected visual acuity (BCVA), cup-to-disc ratio (CDR), visual field mean deviation (VF-MD), increase in the number of glaucoma medications or secondary glaucoma interventions for uncontrolled IOP. Disease severity was classified according to the Hodapp-Anderson-Parrish visual field criteria with VF-MD no worse than − 6 dB classified as mild, between − 6 and − 12 dB as moderate and worse than − 12 dB as severe \[[@CR32]\].

Generalized linear models (GLM) evaluated the 1-year outcomes. Proportional analyses of eyes with IOP ≤ 18 mmHg, ≤ 15 mmHg and ≤ 12 mmHg, and with medication reduction ≥ 0, ≥ 1 and ≥ 2 medications, were performed and compared to the preoperative values. To ensure continuity of data, BCVA scores were converted to the logarithm of minimal angle of resolution (LogMAR). All statistical analyses were performed using SPSS 25.0 (IBM, NY, USA) with significance set at *p* \< 0.05.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

A total of 62 phakic eyes of 42 patients, with an average age of 71.9 ± 7.4 years and baseline IOP of 15.82 ± 2.94 mmHg on 1.50 ± 1.28 glaucoma medications, were included. Most of the eyes (89%) had mild-to-moderate NTG, and the remaining 11% had severe disease. Over three quarters (77%) of the eyes had no prior glaucoma interventions, and the remaining 23% had previously undergone a selective laser trabeculoplasty (SLT) procedure. None of the patients had previously undergone incisional glaucoma surgery. Demographics and baseline characteristics of the eyes are presented in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and preoperative ocular characteristicsVariable*N* = 62 eyes of 42 subjectsAge at time of surgery (years)71.92 ± 7.45Gender (male: female)24: 38Eye (OD: OS)29: 33History of selective laser trabeculoplasty % (*n*)23% (14)Central corneal thickness (μm)542.64 ± 39.76Intraocular pressure (mmHg)15.82 ± 2.94Glaucoma medications1.50 ± 1.28Corrected distance visual acuity (logMar)0.17 ± 0.21Cup-to-disc ratio0.71 ± 0.14Visual field---mean deviation (dB)− 5.62 ± 5.16Visual field---pattern standard deviation (dB)4.76 ± 2.98Retinal nerve fiber layer thickness (μm)76.94 ± 13.09Mean ± standard deviations are presented, where applicable

Efficacy {#Sec9}
--------

Following CE-TMS, both IOP and medication use decreased significantly and consistently throughout the 12-month follow-up. Average IOP decreased by 22% from 15.8 ± 2.9 mmHg preoperatively to 12.3 ± 2.6 mmHg at 12-month follow-up (*p* \< 0.001, Fig. [1](#Fig1){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). As presented in Fig. [2](#Fig2){ref-type="fig"}, proportional analyses highlighted a higher proportion of eyes with lower IOP at follow-up: all eyes had IOP ≤ 18 mmHg (versus 74% preoperatively), 92% had IOP ≤ 15 mmHg (versus 45% preoperatively), and 50% of the eyes had IOP ≤ 12 mmHg (versus 15% preoperatively). The preoperative and the 12-month postoperative IOPs in each patient are presented in Fig. [3](#Fig3){ref-type="fig"}.Fig. 1Postoperative change in intraocular pressure. Following cataract surgery combined with implantation of iStent *inject*, the average intraocular pressure significantly decreased and was maintained throughout follow-up (*p* \< 0.001). \*Denotes statistical significance at *p* \< 0.05, and the error bars represent 95% confidence intervals. Mean ± standard deviations are presentedTable 2Twelve-month outcomes in efficacy and safety measures (*N* = 62 eyes of 42 subjects)VariableBaseline12-Month follow-up*p*-valueIntraocular pressure (mmHg)15.82 ± 2.94 \[9--20\]12.32 ± 2.58 \[8--18\] \< 0.001\*Glaucoma medications1.50 ± 1.28 \[0--5\]0.45 ± 0.86 \[0--4\] \< 0.001\*Corrected distance visual acuity (logMar)0.17 ± 0.21 \[0.0--1.0\]0.04 ± 0.09 \[0.0--0.4\] \< 0.001\*Cup-to-disc ratio0.71 ± 0.14 \[0.40--0.95\]0.73 ± 0.12 \[0.40--0.95\]0.527Visual field---mean deviation (dB)− 5.62 ± 5.16 \[− 29.0 to − 0.5\]− 5.97 ± 5.00 \[− 29.0 to − 0.5\]0.602Visual field---pattern standard deviation (dB)4.76 ± 2.98 \[2--13\]4.38 ± 2.74 \[1--12\]0.483Retinal nerve fiber layer thickness (μm)76.94 ± 13.09 \[52--114\]77.75 ± 14.14 \[50--114\]0.777Mean ± standard deviations are presented and statistically compared\*Denotes statistical significance\[\] Represents rangeFig. 2Percentages of eyes with IOP ≤ 18, ≤ 15 and ≤ 12 mmHg preoperatively and at 1-year follow-up. Solid and checked bars represent preoperative and 1-year follow-up data, respectively; *IOP* intraocular pressureFig. 3Preoperative and 1-year postoperative intraocular pressure in each eye

The average number of glaucoma medications decreased by 70% from 1.50 ± 1.28 medications preoperatively to 0.45 ± 0.86 medications at follow-up (*p* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). At 1-year postoperatively, medication use decreased by at least one medication among 66% and by at least two medications among 29%. Furthermore, 73% of the eyes were medication-free (versus 23% preoperatively) and only 13% were on two or more glaucoma medications (versus 39%, Fig. [5](#Fig5){ref-type="fig"}). No patient required an increase in the number of medications following surgery.Fig. 4Postoperative change in the number of glaucoma medications. Following cataract surgery combined with implantation of iStent *inject*, the mean number of medications significantly decreased and was maintained throughout follow-up (*p* \< 0.001). \*Denotes statistical significance at *p* \< 0.05, and the error bars represent 95% confidence intervals. Mean ± standard deviations are presentedFig. 5Left panel (left of the dotted line) illustrates the percentage of the eyes with reductions of ≥ 0, ≥ 1 or ≥ 2 medication(s) at 1-year follow-up. The right panel demonstrates the percentage of the eyes that are medication-free or on ≥ 2 medications preoperatively (checked bars) and at 1-year follow-up (solid bars). Med: medication: reduction in the number of anti-glaucoma medications

At the time of this study, iStent *inject* was approved for OAG with mild-to-moderate severities. Therefore, we performed a subgroup analysis excluding the severe cases. A total of 55 mild and moderate NTG eyes with an average age of 71.4 ± 7.7 were included. Preoperative IOP was 15.90 ± 2.93; the mean number of glaucoma medications was 1.44 ± 1.21. The primary outcomes were similar to those of the overall cohort. IOP decreased by 21.3% to 12.51 ± 2.52 (*p* \< 0.001), and the number of glaucoma medications decreased by 75% to 0.36 ± 0.78 (*p* \< 0.001). These outcomes were not significantly different from those of the severe cases either (*p* \> 0.05).

Safety {#Sec10}
------

All eyes successfully underwent CE-TMS with no intraoperative complications. BCVA improved by six letters of acuity (*p* \< 0.001). No evidence of disease progression was noted within the first postoperative year, with stable CDR (*p* = 0.527), VF-MD (*p* = 0.602), VF-PSD (*p* = 0.483) and RNFL thickness (*p* = 0.777).

Postoperative adverse events were rare and self-limiting; IOP spike (IOP increase by 10 mmHg or ≥ 50% above baseline) \[[@CR26], [@CR33]\] occurred in four eyes (6.5%), and transient corneal edema was evidenced in five eyes (8.1%), all within the first postoperative week. No evidence of sight-threatening adverse events, endophthalmitis, hypotony, choroidal detachment, corneal decompensation, rebound iritis or stent obstruction was noted. None of the eyes underwent any further glaucoma interventions (including SLT) or surgeries within the first postoperative year.

Discussion {#Sec11}
==========

The favorable safety and efficacy of the iStent *inject* trabecular micro-bypass stents has been well documented, with most evidence focusing on patients with mild-to-moderate POAG \[[@CR19]--[@CR27]\]. To the best of our knowledge, the present study is the first to exclusively examine the utility and safety of iStent *inject* in patients with NTG.

Considering the difficulty of treating NTG and the widely known risks of more aggressive filtering procedures \[[@CR7], [@CR34], [@CR35]\], this report contributes useful information on a minimally invasive surgical approach to treat this population.

The results of our study highlighted meaningful reductions in IOP and medication use throughout 1 year following implantation of iStent *inject* in combination with cataract surgery. Given the well-known pattern of less dramatic IOP reduction in eyes with lower baseline IOP \[[@CR36]--[@CR38]\], it is not surprising that the IOP reduction (3.5 mmHg) observed in these normotensive eyes was more modest than the reductions achieved in prior studies of iStent *inject* with phacoemulsification in predominantly POAG patients \[[@CR19], [@CR22], [@CR23], [@CR26], [@CR39]\]. Although the mean IOP reduction of 3.5 mmHg could be seen as modest, it is still noteworthy given patients' normotensive preoperative IOP and the critical role of IOP reduction even in eyes with normal pressures \[[@CR3], [@CR6]\].

The significant reduction in medication use in this study is compelling. At baseline, 39% of eyes were on two or more glaucoma medications. In contrast, by the end of the follow-up period, the number of medications had decreased by 70%, only 13% of eyes were on two or more medications, and 73% of eyes had eliminated medications entirely. This reduction in medication dependence is valuable in the context of the recognized difficulties with medication adherence, medication-induced ocular surface damage, local and systemic side effects, medication costs and potentially diminished quality of life \[[@CR13], [@CR15], [@CR16], [@CR20], [@CR40]\].

The safety profile in this study was highly favorable and confirms the current literature showing that adding iStent *inject* implantation to concomitant cataract surgery confers minimal to no additional risk beyond cataract surgery alone \[[@CR41]\]. There was a low rate of adverse events postoperatively and no cases of severe intra- or postoperative complications. All adverse events were transient and self-limiting without sequelae. Furthermore, no patients required a secondary glaucoma intervention (laser or surgery) for continued disease progression or uncontrolled IOP in the postoperative period. The fact that these outcomes were achieved in the setting of different surgeons, sites and countries demonstrates the consistency of the device's favorable safety profile regardless of setting.

This retrospective case series had certain limitations. Given the retrospective nature of the study, there was no washout phase, and strict inclusion/exclusion criteria such as those observed in clinical trials were not employed; however, it has been established that in addition to randomized control trials, real-world data are essential in health care policy-making---as the results of these studies are likely more generalizable to the real-world clinical practice \[[@CR42]\]. In this combined procedure, the lack of a control arm limits our ability to predict to what degree the observed improvements could be attributed to the efficacy of the iStent *inject* alone. It is known that cataract surgery alone can lower IOP in patients with POAG; however, the evidence regarding NTG is limited. A recent study evaluating the efficacy of cataract surgery in NTG reported reductions in IOP by a mean of 2.7 mmHg and medication use by an average of 0.82 medications at 6 months postoperatively \[[@CR43]\]. A more recent study by Baek and colleagues assessed the outcomes of cataract surgery in both normal and glaucomatous eyes at 1 year and beyond \[[@CR44]\]. A sub-analysis of the outcomes in their NTG population evidenced a mean IOP reduction of 0.78 mmHg. These results contrast to ours which evidenced reductions in IOP by a mean of 3.5 mmHg and in medication use by an average of 1.05 medications. It is worth noting that these results should be interpreted in the context of the differences between the studies including the postoperative follow-up duration as well as the baseline clinical differences. Head-to-head studies comparing the outcomes related to CE-TMS versus cataract extraction as a standalone procedure are warranted.

Despite the above-mentioned limitations, the results of this study are compelling and support further investigation, particularly given the paucity of evidence regarding the use of iStent *inject*---and MIGS procedures more broadly---exclusively in eyes with NTG. Future prospective large-scale studies would be helpful to further elucidate the role of not only iStent *inject* trabecular micro-bypass, but also the category of MIGS procedures as a whole in the surgical treatment of NTG. Additionally, given the challenge of lowering IOP below the physiologic limitation of episcleral venous pressure (EVP) with MIGS procedures alone, future studies could evaluate the augmentation of MIGS procedures with other minimally invasive surgical or medical interventions for IOP reduction.

Conclusion {#Sec12}
==========

To our knowledge, this is the first published report exclusively evaluating the outcomes of iStent *inject* trabecular micro-bypass with cataract surgery in NTG, a population that has not often been studied with respect to trabecular micro-bypass stents or other MIGS procedures. This report\'s favorable results support the use of the device in this population, in particular for patients hoping to reduce their topical medication regimen and avoid the risks associated with filtering procedures.
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